explore -WSS

explore

author：Wikipedia 2025-09-27 19:27:45 - browse：59734

The experimental Alzheimer’s drug lecanemab, hailed after it slowed patients’ cognitive decline in a clinical trial, may have contributed to the death in June of a patient in the study, STAT has learned.

One investigator on the study flagged the death, noting it came after the patient experienced bleeding in the brain, and concluded it was related to the drug, according to documents obtained by STAT. Eisai, the drugmaker behind lecanemab, disagreed, pointing to other possible factors, including a series of setbacks in preceding months — multiple falls, a heart attack, a respiratory infection, and mini-stroke-like events.

Though still under investigation, the death suggests that new medicines to treat Alzheimer’s, like medicines to treat anything else, will come with their own side effects and costs. It also raises the importance of waiting for the full lecanemab data before drawing conclusions based on the positive press release put out by Eisai and its partner Biogen last month.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： After affirmative action ruling, medical educators look to 'holistic review'
Next article： Organ aging and disease risk measured by new blood test

WSS

Fetal surgery at risk from Dobbs and new abortion restrictions

More people are opting for early dinners since the pandemic, says OpenTable CEO Debby Soo

The UK government moves asylum

BIO selects John Crowley as new CEO

Diagnostic tests are hitting their mathematical limits

In medicine, common shorthands can shortchange care

focus

explore

leisure time

In age of alternative facts, a scholarly course on calling out crap

Prince Harry and Meghan to work on film adaptation of 'Meet Me at the Lake' novel

Jerome Adams on the need for new antivirals for Covid

What don’t we know about an Alzheimer’s drug side effect?

State Dept. review finds Biden bears some blame for Afghanistan failures

BIO selects John Crowley as new CEO

The high cost of giving birth even with insurance

Democratic lawmaker calls for 'well

Guidelines to prevent youth baseball injuries need more muscle

Israel demolishes home of alleged Palestinian attacker, fueling West Bank tensions

focus

DeSantis and Newsom agree to Sean Hannity debate, then disagree on the rules

30 years of 'Listening to Prozac'

Boeing's 1st astronaut flight bumped into next year, more repairs needed

Nearly a dozen Russian and Chinese ships now moving away from Alaska, officials say

Mississippi candidates for statewide offices square off in party primaries

What to do when lifesaving products contribute to climate change

explore

explore

entertainment

hotspot